Objective: To investigate the dose -response effects of a novel fat emulsion (Olibra TM ) on energy and macronutrient intakes up to 36 h post-consumption in non-overweight subjects. Design: A single-blind, placebo-controlled, within-subject cross-over design was used. Setting: Metabolic suite of the University of Ulster, Coleraine. Subjects: Fifty subjects (30 female, 20 male) from the student and staff population of the University of Ulster, Coleraine. Interventions: Subjects were given in random order, 7 days apart, a 200 g portion of yoghurt containing a total of 15 g of fat, which varied in quantity of Olibra TM fat (0, 2, 4, 6 g) at 09:00 h. At 13:00 h subjects were given ad libitum access to a range of foods. Amounts of food consumed were measured by covert pre-and post-consumption weighing of individual serving dishes. For the remainder of the day and the following 24 h, subjects weighed and recorded all food intakes. 39.3, 38.2, 39.6% energy), intakes were progressively reduced with increasing doses of Olibra TM fat in the total group (P < 0.001). A similar response was observed in the female group up to 4 g (P < 0.001) and in the male group after 2 and 6 g (P < 0.05). Energy and macronutrient intakes for the remainder of each study day and over the following 24 h were significantly lower after all dose levels compared to the control (P < 0.001).
Introduction
Although current research suggests that fat is the least satiating of the macronutrients (Rolls & Hammer, 1995) , the issue remains unresolved (Welch et al, 1988; de Graaf et al, 1992; Blundell et al, 1996) . It is possible that methodological differences between study designs may have contributed to this controversy (Rolls et al, 1988; de Graaf et al, 1992) . Differences in meal type (Kissileff, 1984) , energy density and macronutrient composition (Prentice & Poppitt, 1996; Westerterp-Plantenga et al, 1996; Bell et al, 1998) , duration of time between a preload and a test meal (Rolls et al, 1991a; Horn et al, 1996; Melanson et al, 1999) and characteristics of subject populations (Drewnowski et al, 1985; Mela & Sacchetti, 1991) have all been shown to influence the satiating efficiency of fat. Furthermore, different physicochemical properties of fats could influence their satiating properties. These include fatty acid chain length (Bach et al, 1996; Stubbs & Harbon, 1996; Van Wymelbeke et al, 1998) , degree of fatty acid unsaturation (Shimomura et al, 1990; Lawton et al, 1997; Kamphuis et al, 2001) , degree of emulsification (Welch et al, 1985 (Welch et al, , 1988 and emulsion stability (Armand et al, 1992) . In this context it has recently been shown that a fat emulsion (Olibra TM ) formulated from palm oil and oat oil fractions significantly decreased energy and macronutrient intakes in lean, overweight and obese subjects up to 36 h post-consumption (Burns et al, 2000 (Burns et al, , 2001 . The aim of the present study is to investigate if the responses to this novel fat emulsion and the subsequent effects of these on food intakes are dose-dependent.
Subjects and methods

Subjects
Fifty subjects (30 females, 20 males) were recruited by poster advertisement from the student and staff population at the University of Ulster. The study protocol was explained in detail to each subject, and the subjects who met the eligibility criteria and agreed to take part gave their written informed consent. Inclusion criteria were: body mass index (BMI) 20 -25 kg=m 2 , non-smokers, non-vegetarians, nonrestrained eaters as assessed by the Dutch Eating Behaviour Questionnaire (Van Strien et al, 1986) , not taking any prescription medication and non-participants in any previous study using Olibra TM fat. The weight, height and percentage body fat (bioelectrical impedance Bodystat 1500, Bodystat Ltd, Isle of Man, UK) of each subject were measured prior to breakfast on the first study day. The study was approved by the Research Ethical Committee of the University of Ulster.
Study design
This study was conducted over 3 months in the metabolic suite at the University of Ulster. The metabolic suite consists of a food preparation area, which is separate from an independent dining area, where six subjects can eat comfortably. The study design was a randomised, single-blind, placebocontrolled, within-subject cross-over. Each subject was studied on four occasions, on the same day of each week, and with a one-week interval between study days. Each subject came to the metabolic suite at 18:00 h on the evening prior to each study day and consumed (on each occasion) the same evening meal in terms of weight of food, energy and macronutrient composition. Subjects were asked to refrain from moderate-to-heavy exercise on each study day and on the day before and the day after each study day. After the evening meal prior to each study day, subjects were requested to fast from 20:00 h until 08:45 h the following day, when they came to the metabolic suite and consumed a 200 g portion of yoghurt containing varying doses of Olibra TM fat or a control containing only milk fat. After eating the yoghurt, subjects remained in the metabolic suite and were not permitted to consume anything other than uncarbonated water, if required. At 13:00 h subjects were given ad libitum access to a range of sweet and savoury foods compatible with the stated food preferences of the subjects. Uncarbonated water was available to drink at meal times. All foods presented at 13:00 h were covertly weighed prior to the meal, and all uneaten food was weighed after the meal when the subjects had left the metabolic suite. Intakes were assessed by difference. After the lunch meal subjects were free to leave the metabolic suite. For the remainder of the day, and up until 21:00 h the following day, subjects were permitted to eat and drink as they wished, but were instructed to keep a weighed record of all food and beverages consumed during this period using a set of weighing scales (Digital Scale, Model 308, Ravencourt Ltd, UK) and a food diary. 
Test foods
Lunch meal
The lunch meal was a buffet-style, self-selection meal that allowed ad libitum consumption of a variety of foods that varied in macronutrient composition (Table 1 ). All foods were served in larger than estimated average portions so that choice was not restricted by quantity. Different types of food were served in separate serving dishes so as not to influence food combination choices. Unlimited eating time was given to each subject. Uncarbonated water was available to drink.
Assessment of appetite
Subjects rated their hunger, desire to eat and perceived fullness on visual analogue scales (VAS; in mm) by the pen and paper method. For example, hunger was rated on a 100 mm line preceded by the question 'How hungry do you feel?' and anchored on the left by 'not at all hungry' and on the right by 'as hungry as I have ever felt'. The other anchors for the questions on desire to eat and perceived fullness consisted of the phrases 'very weak . . . ' against 'very strong . . . ', and 'not Dose -response effect of Olibra TM AA Burns et al at all . . . ' against 'extremely full . . . ', for each of the questions, respectively. Subjects were instructed to make a single vertical mark at the appropriate point between the two anchors on each scale to indicate their subjective feelings of hunger, desire to eat and perceived fullness, respectively, at defined time points (immediately before and after eating the yoghurt and thereafter at hourly intervals until 21:00 h on all study days). Yoghurts were rated for pleasantness of taste by the subjects using a VAS form 15 min post-consumption of all yoghurts.
Statistical analysis
Energy (MJ) and macronutrient (g) intakes, and the weight (g) of the food consumed at the ad libitum lunch meal, subsequent evening meal and snacks, and intakes for the following 24 h were analysed using Wisp 1.28 C (Tinuviel Software, 2 Penmark Close, Warrington, UK). The data from the total group and the female and male groups separately at 4 h post-consumption were analysed using a general linear mixed effects model. Subjects were treated as random and the fixed effects were treatment, treatment-order, treatment period and 'carry-over'. The treatment effect refers to the energy and macronutrient intakes after the test yoghurts relative to their intake after the control yoghurt. The treatment-order effect compared the intakes of the subjects who received the varying doses of Olibra TM fat in different order (group 1, 0 g; group 2, 2 g; group 3, 4 g; group 4, 6 g). The 'carry-over' term represents the possible effects of treatment in one treatment period carrying over to the next treatment period. Differences in 'carry-over' should not be present because they contaminate the data from the second, third etc treatment periods. Non-significant (P > 0.05) 'carry-over' terms were omitted from the model when testing treatment effects. The energy and macronutrient intakes for the remainder of the evening and the following 24 h for the total group of subjects were analysed by a general linear model procedure (Jones & Kenward, 1989) . Analyses of energy and macronutrient intakes were performed using the SAS statistical program (SAS Institute Inc., Cary, NC, USA).
The visual analogue ratings were analysed using a mixed procedure model by calculating a mean rating for each 14 h (pre-and post-yoghurt, 10:00 -21:00 h) period. Real mean values were used for reporting hunger, desire to eat, fullness and pleasantness of taste ratings. VAS were analysed using the SAS statistical program (SAS Institute Inc., Cary, NC, USA). Results were considered significant at the P < 0.05 level.
Results
Subjects
No subjects reported any ill effects or discomfort after consumption of any of the yoghurts. The male subjects were significantly older, taller and had significantly higher BMIs and lower percentage body fat than the female subjects (P < 0.05 for each parameter; Table 2 ). Significantly different from male subjects (P < 0.05).
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Energy and macronutrient intakes at the lunch meal The mean energy and macronutrient intakes, the total weight of food and water consumed 4 h post-consumption of all yoghurts for the total group are presented in Table 3 , while the data for female and males groups separately are presented in Table 4 . For the total group of subjects and the female and male groups there was no evidence of a treatment-order or 'carry-over' effect at the ad libitum meal 4 h post-consumption of the test yoghurts. Thus, non-significant (P > 0.05) interaction terms were omitted from the model when testing treatment effects.
Relative to the control conditions, the energy intakes (MJ) in the total group were lower by 21, 25 and 30% after the 2, 4 and 6 g doses, respectively (P < 0.001 at each dose level; Table 3 ). The corresponding macronutrients (g) and weight of food (g) were also significantly lower (P < 0.001 at each dose level). Water intakes (ml) at each dose level were not significantly different from the control condition (P > 0.05). However, the differences between doses were not significant, with the exception of the 6 g dose where energy (P < 0.05), protein (P < 0.01) and carbohydrate (P < 0.05) intakes were significantly lower compared to the 2 g dose of Olibra TM fat. In the female group, energy (MJ) and macronutrient intakes (g) and the total weight of food (g) were also significantly lower following consumption of all doses of Olibra TM fat relative to the control condition (P < 0.05 at each dose level; Table 4 ). However, intakes of energy, fat, protein and carbohydrate following the 4 and 6 g doses were broadly similar. Compared to the lowest dose of 2 g of Olibra TM fat, intakes of energy (P < 0.05), carbohydrate (P < 0.05) and the total weight of food (P < 0.05) were significantly lower after the ingestion of the 4 and 6 g doses, and protein (P < 0.05) after the 6 g dose. Water intakes (ml) at each dose level were not significantly different from the control condition (P > 0.05).
Only at the 2 and 6 g dose levels were energy (MJ) and macronutrients (g) significantly lower in the male subjects relative to the control condition (P < 0.05 at each dose level; Table 4 ). Following the consumption of 4 g of Olibra TM fat, energy (MJ), fat (g), protein (g) and carbohydrate (g) intakes together with the total weight of food (g) were not significantly different from those of the control condition. However, after the 6 g dose there were significantly lower intakes of energy (P < 0.05), fat (P < 0.05) and protein (P < 0.05) compared to the lower dose of 4 g (Table 4 ). Similarly to the female subjects there was no significant difference in water intakes (ml) at each dose level compared to the control condition (P > 0.05).
Energy and macronutrient intakes for the remainder of the evening and the following 24 h There were no significant differences in energy intakes between the female and male subjects for the remainder of the evening and the following 24 h and therefore results are shown for the total group in Figures 1 and 2 . At both times, intakes of energy (MJ) and the corresponding macronutrients (g) were significantly lower (P < 0.001) after each dose level compared to the control, but the reductions between dose levels of Olibra TM fat were not significant. A 'carry-over' effect was observed in the self-recorded food intakes. This 'carry-over' effect represents the effects of one treatment period carrying over to the next treatment period. However, as there was a 7 day interval between each study day this 'carry-over' effect is most likely to be a consequence of outliers in the data.
Subjective hunger, desire to eat, fullness and pleasantness of yoghurts The mean ratings for hunger, desire to eat and perceived fullness after all doses of Olibra TM fat over each study day are shown in Figures 3 -5. There were no significant differences Dose -response effect of Olibra TM AA Burns et al in hunger, desire to eat or perceived fullness between the varying doses of Olibra TM fat and the control yoghurt. No significant differences in the subjectively rated pleasantness of taste of the yoghurts were observed (Table 5) .
Discussion
The present study confirms previous observations that yoghurt containing Olibra TM fat significantly reduces energy and macronutrient intakes relative to milk fat Figure 1 Mean AE s.e.m. energy intakes (MJ) for the remainder of each study day and total intake for the day, for the total group (n ¼ 50). *Significantly different from control (P < 0.05).
Dose -response effect of Olibra TM AA Burns et al (Burns et al, 2000 (Burns et al, , 2001 . The present study has also shown that, when using a dose-response paradigm, which is a sensitive test of differences in satiety (Rolls & Hammer, 1995) , the effects of Olibra TM fat generally increase with increasing doses. The results suggest that the reductions in food intake were by a non-specific reduction in overall energy intake, given that the percentages of energy from the macronutrients were not significantly different under test and control conditions. However, a greater fat-specific satiety may be expected in the medium-to-long term given that the test yoghurts contained a higher amount of linoleic acid which has been shown to induce fat-specific satiety (Beardshall et al 1989; Lawton et al, 1997; Kamphuis et al, 2001) .
In the total group, energy intakes were lower by 21% (1.59 MJ), 25% (1.82 MJ) and 30% (2.18 MJ) after the 2, 4 and 6 g dose levels, respectively, compared to the control condition. Overall this indicates that the minimum dose tested (2 g) gives a significant and substantial lowering of energy intakes, and that although two-fold or three-fold increases in the dose enhanced the responses, these enhancements were not proportional to the dose. This suggests that it may be informative to evaluate response at doses below the minimum 2 g evaluated here. However, there were some interesting differences in response between males and females. While both the male and female group showed significant lowering of energy intakes after the 2 g dose, the response was greater in the females (25%; 1.74 MJ) than in the males (16%; 1.32 MJ). In the female group, the response increased with the 4 g dose (34%; 2.4 MJ) but showed no further increase at the 6 g dose. In contrast the response of the male group was lower after the 4 g dose (11%; 0.87 MJ), but increased further after the 6 g dose (23%; 1.86 MJ). In a previous experiment where a 5 g dose was tested in two separate but similar studies, it was found that males gave very similar reductions in energy intake (10%; 0.89 MJ and 11%; 1.00 MJ), and these are in close agreement with those reported here with the 4 g dose (Burns et al, 2000) . However, in the previous experiment the females gave somewhat divergent responses to the 5 g dose (22%; 1.48 MJ and 14% 0.95 MJ) and those responses were lower than that observed at the 4 g dose in the present study. This inconsistency is attributed to unexplained experimental variables, such as unaccounted for variations in subject characteristics. However, overall it is apparent that female subjects respond more than males, regardless of dose and there are a number of possible explanations for this. These include gender Dose -response effect of Olibra TM AA Burns et al differences in food intake and selection (Rolls et al, 1991b) or that, as a result of their lower body weight, the females received higher doses of Olibra TM fat per kg body weight. This latter explanation seems plausible, since in this experiment, at each dose level, the females received 28% more Olibra TM fat than the males on a per kg body weight basis. In the present study it is not possible to make any comparisons between females and males where the doses are similar on a per kg body weight basis. However, a comparison can be made with data from the earlier report where the doses for females were 82 mg Olibra TM fat per kg body weight in both studies, and energy intakes were lower by 22 and 14% (1.48 and 0.95 MJ; Burns et al, 2000) . These responses are similar to that found for males in the present study at the 6 g dose level, where the energy intake was lower by 23% (1.86 MJ), and the dose was 79 mg Olibra TM fat per kg body weight. Under control conditions the energy intake (14.0 MJ) for the total group on the first study day was 40% higher than energy intake (8.4 MJ) on the second day. The validity of the observed intakes at lunch on day one suggests that the high energy intakes during this study day are probably a consequence of over-eating. The wide range of foods on offer at the buffet lunch may have undermined normal physiological satiety signals. On the other hand, it is possible that the energy intake on the second study day could reflect not only under-eating as a compensatory response to over-eating on day one but also under-reporting of this lower food intake. The data from the self-reported food diaries of energy and macronutrient intakes for the remainder of the study day, and also over the following day, suggest that the suppression of food intake under test conditions continued over this period, with the greatest difference observed after 6 g of Olibra TM fat. The 'carry-over' effect observed in the selfrecorded food intakes was most likely a consequence of the number of outliers in the data. These outlying data may be a result of the mis-reporting of food intakes, since self-reported food intakes are well recognised to be susceptible to underreporting (Livingstone et al, 1990; Black et al, 1993) . Dose -response effect of Olibra TM
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It has been suggested that the observed lowering in energy and macronutrient intakes following the consumption of Olibra TM fat was a result of the 'ileal-brake' mechanism (Burns et al, 2000 (Burns et al, , 2001 , ie the inhibition of upper gastrointestinal functions elicited by the presence of unabsorbed nutrients in the ileum (Zhao et al, 2000) . The 'ileal-brake' appears to be related to the release of one or more peptide hormones from the distal intestine. This study has not tested for metabolic effects after the consumption of Olibra TM fat. However, as the 'ileal-brake' has been shown to be dosedependent (Pironi et al, 1993) , this is compatible with the present results, given that when dose levels of Olibra TM fat increased, energy and macronutrient intakes were further lowered. Thus, it may be that Olibra TM is acting through an increased and prolonged release of peptides such as peptide YY (Pironi et al, 1993) , cholecystokinin (Lieverse et al, 1994; Smith & Gibbs, 1994) , glucagon-like peptide-1 (Naslund et al, 1998; Giralt & Vergara, 1999) , or enterostatin (ErlansonAlbertson & York, 1997; Lin et al, 1997) which are known to influence satiety through the 'ileal-brake'.
In conclusion, this study has shown that the effects of Olibra TM increase with increasing doses but results are not consistent across gender or dose levels and further work is required to establish if the maximum effective dose is dependent upon body weight.
